Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.3M, a diversified technology company, has announced that its drug delivery systems division has signed an exclusive technology licensing and purchase agreement with Cambridge Consultants for its Conix dry powder inhaler technology platform.
Subscribe to our email newsletter
3M has operations in six business segments. It offers a range of feasibility, development and manufacturing capabilities combined with regulatory guidance to help bring products to market. It also offers in-house resources, which include toxicology, regulatory expertise, quality assurance, operations, and marketed product support, for each step of the development and commercialization process.
The Conix technology platform includes a variety of inhaler types, ranging from a single dose device suitable for applications such as immunizations, to a multi-unit dose suitable for therapies such as asthma and chronic obstructive pulmonary disease.
The Conix dry powder inhaler technology, also called reverse-flow cyclone technology, adds to 3M’s inhalation technology platform.
James Vaughan, vice president of 3M’s drug delivery systems division, said: This new technology platform enhances 3M’s capability to provide partner pharmaceutical and biotechnology companies with innovative drug delivery solutions. We believe the Conix technology will add to the breadth of our unique inhalation technology portfolio and enables us to offer new and exciting drug delivery alternatives.